The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Flotetuzumab for primary refractory and early relapsed AML
John DiPersio, MD, PhD, Washington University School of Medicine, Saint Louis, MO, presents additional scientific data supporting the investigation of flotetuzumab, a CD123 x CD3 bispecific DART molecule, in salvage therapy for primary refractory and early relapsed acute myeloid leukemia patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
